# A Study to Evaluate the Safety, Tolerability, Pharmacokinetics (PK), and Antitumor Activity of ALK201 in Participants With Advanced Solid Tumors

Source: https://onco.cc/trials/nct06656390/  
OnCo record `nct06656390` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 1/2 trial of ALK201 in advanced solid tumours, run by Shanghai Allink Biotherapeutics Co., Ltd., now recruiting.

## Summary

A Study to Evaluate the Safety, Tolerability, Pharmacokinetics (PK), and Antitumor Activity of ALK201 in Participants With Advanced Solid Tumors is a phase 1/2 interventional study registered as NCT06656390 by Shanghai Allink Biotherapeutics Co., Ltd., with 202 participants planned, started 2024-10-24 and due to reach its primary completion in 2027-10-22. Interventions recorded: ALK201.

## Fields

- Kind: Trial
- Status: recruiting
- Last checked: 2026-09-16
- Tags: pipeline; ctgov-ingest
- Registry id: NCT06656390
- Phase: 1/2
- Setting: A First-in-Human, Open-Label, Multi-Center Phase I/II Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Antitumor Activity of ALK201 for Injection in Adult Participants With Advanced Solid Tumors
- Sponsor: Shanghai Allink Biotherapeutics Co., Ltd.
- Enrolled: 202

## Sources

- ClinicalTrials.gov NCT06656390: https://clinicaltrials.gov/study/NCT06656390

## Connected records

- cancers: [Metastatic cancer (cancer that has spread)](https://onco.cc/cancers/metastatic-cancer/)

---
JSON: https://onco.cc/api/v1/entities/nct06656390.json